Literature DB >> 24250983

The effect of cyanosis on active clotting time during diagnostic catheterization.

Akbar Molaei1, Majid Malaki, Shahram Sadegvand.   

Abstract

INTRODUCTION: Cardiac catheterization is a common procedure which needs a careful coagulation monitoring. In our study, we aimed to find factors influencing active clotting time (ACT) following heparin therapy.
METHODS: ACT of 71 patients who were scheduled to undergo transcutaneous diagnostic catheterization and angiography were measured at baseline, 2 and 60 minutes after 50 IU/kg heparin loading. ACT in two groups of patients (cyanotic and non-cyanotic) was compared. All data were analyzed with Wilcoxon, Mann-Whitney test and Pearson in SPSS 16, P value less than 0.05 was considered significant.
RESULTS: ACT following heparin at 2nd and 60th minutes was not significantly different in cyanotic and non-cyanotic groups. At 60th minute following heparin administration, ACT decreased more dramatically in older children.
CONCLUSION: Cyanosis does not affect ACT measures following heparin treatment. Moreover, after 60 minutes, heparin efficacy (ACT values) decreased more with increase in patients' age.

Entities:  

Keywords:  Active Clotting Time; Catheterization; Cyanosis; Heparin

Year:  2012        PMID: 24250983      PMCID: PMC3825358          DOI: 10.5681/jcvtr.2012.012

Source DB:  PubMed          Journal:  J Cardiovasc Thorac Res        ISSN: 2008-5117


  13 in total

1.  Variability of the activated coagulation time.

Authors:  G P Gravlee; L D Case; K C Angert; A T Rogers; G S Miller
Journal:  Anesth Analg       Date:  1988-05       Impact factor: 5.108

2.  Age-related differences in heparin sensitivity and heparin-protamine interactions in cardiac surgery patients.

Authors:  C D'Errico; J R Shayevitz; S J Martindale
Journal:  J Cardiothorac Vasc Anesth       Date:  1996-06       Impact factor: 2.628

3.  Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.

Authors:  G J Despotis; A L Summerfield; J H Joist; L T Goodnough; S A Santoro; E Spitznagel; J L Cox; D G Lappas
Journal:  J Thorac Cardiovasc Surg       Date:  1994-12       Impact factor: 5.209

4.  Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass.

Authors:  A T Culliford; S N Gitel; N Starr; S T Thomas; F G Baumann; S Wessler; F C Spencer
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

5.  Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.

Authors:  T F Slaughter; J B Mark; H El-Moalem; K A Hayward; A K Hilton; L P Hodgins; C S Greenberg
Journal:  Blood Coagul Fibrinolysis       Date:  2001-01       Impact factor: 1.276

6.  Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass.

Authors:  J H Chung; N Gikakis; A K Rao; T A Drake; R W Colman; L H Edmunds
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

7.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?

Authors:  S J Brister; F A Ofosu; M R Buchanan
Journal:  Thromb Haemost       Date:  1993-08-02       Impact factor: 5.249

9.  Activated coagulation time method for control of heparin is reliable during cardiopulmonary bypass.

Authors:  J A Cohen
Journal:  Anesthesiology       Date:  1984-02       Impact factor: 7.892

10.  Impact of different Asian ethnic groups on correlation between heparin dose, activated clotting time and complications in percutaneous coronary intervention.

Authors:  Chi-Hang Lee; Esther Tan; Hwee-Bee Wong; Edgar Tay; Huay-Cheem Tan
Journal:  Int J Cardiol       Date:  2007-08-16       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.